Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Medicine
Volume 2015, Article ID 767198, 6 pages
http://dx.doi.org/10.1155/2015/767198
Case Report

Two Cases of Sarcoma Arising in Giant Cell Tumor of Bone Treated with Denosumab

1Department of Pathology, University of New Mexico School of Medicine, MSC08 4640, 1 University of New Mexico, Albuquerque, NM 87131, USA
2Department of Orthopaedics, University of New Mexico School of Medicine, MSC10 5600, Albuquerque, NM 87131, USA
3Department of Radiology, University of New Mexico School of Medicine, MSC10 5530, 1 University of New Mexico, Albuquerque, NM 87131, USA

Received 29 August 2015; Revised 2 December 2015; Accepted 3 December 2015

Academic Editor: Gottfried J. Locker

Copyright © 2015 Cory Julian Broehm et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. N. Athanasou, M. Bansal, R. Forsyth, R. Reid, and Z. Sapi, “Giant cell tumour of bone,” in WHO Classification of Tumours of Soft Tissue and Bone, C. D. M. Fletcher, J. Bridge, P. Hogendoorn, and F. Mertens, Eds., pp. 321–324, IARC Press, Lyon, France, 4th edition, 2013. View at Google Scholar
  2. F. M. Klenke, D. E. Wenger, C. Y. Inwards, P. S. Rose, and F. H. Sim, “Giant cell tumor of bone: risk factors for recurrence,” Clinical Orthopaedics and Related Research, vol. 469, no. 2, pp. 591–599, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. F. M. Klenke, D. E. Wenger, C. Y. Inwards, P. S. Rose, and F. H. Sim, “Recurrent giant cell tumor of long bones: analysis of surgical management,” Clinical Orthopaedics and Related Research, vol. 469, no. 4, pp. 1181–1187, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. F. Masui, S. Ushigome, and K. Fujii, “Giant cell tumor of bone: a clinicopathologic study of prognostic factors,” Pathology International, vol. 48, no. 9, pp. 723–729, 1998. View at Publisher · View at Google Scholar · View at Scopus
  5. D. J. McDonald, F. H. Sim, R. A. McLeod, and D. C. Dahlin, “Giant-cell tumor of bone,” The Journal of Bone & Joint Surgery—American Volume, vol. 68, no. 2, pp. 235–242, 1986. View at Google Scholar · View at Scopus
  6. K. A. Siebenrock, K. K. Unni, and M. G. Rock, “Giant-cell tumour of bone metastasising to the lungs,” The Journal of Bone & Joint Surgery—British Volume, vol. 80, no. 1, pp. 43–47, 1998. View at Publisher · View at Google Scholar · View at Scopus
  7. F. Bertoni, P. Bacchini, and E. L. Staals, “Malignancy in giant cell tumor of bone,” Cancer, vol. 97, no. 10, pp. 2520–2529, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. M. G. Rock, F. H. Sim, K. K. Unni et al., “Secondary malignant giant-cell tumor of bone,” The Journal of Bone and Joint Surgery—American Volume, vol. 68, no. 7, pp. 1073–1079, 1986. View at Google Scholar · View at Scopus
  9. A. G. Nascimento, A. G. Huvos, and R. C. Marcove, “Primary malignant giant cell tumor of bone: a study of eight cases and review of the literature,” Cancer, vol. 44, no. 4, pp. 1393–1402, 1979. View at Publisher · View at Google Scholar · View at Scopus
  10. D. M. Thomas, “RANKL, denosumab, and giant cell tumor of bone,” Current Opinion in Oncology, vol. 24, no. 4, pp. 397–403, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. L. Huang, J. Xu, D. J. Wood, and M. H. Zheng, “Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation,” The American Journal of Pathology, vol. 156, no. 3, pp. 761–767, 2000. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Chawla, R. Henshaw, L. Seeger et al., “Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study,” The Lancet Oncology, vol. 14, no. 9, pp. 901–908, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. D. Thomas, R. Henshaw, K. Skubitz et al., “Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study,” The Lancet Oncology, vol. 11, no. 3, pp. 275–280, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. L. A. Aponte-Tinao, N. S. Piuzzi, P. Roitman, and G. L. Farfalli, “A high-grade sarcoma arising in a patient with recurrent benign giant cell tumor of the proximal tibia while receiving treatment with denosumab,” Clinical Orthopaedics and Related Research, vol. 473, no. 9, pp. 3050–3055, 2015. View at Publisher · View at Google Scholar
  15. D. G. Branstetter, S. D. Nelson, J. C. Manivel et al., “Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone,” Clinical Cancer Research, vol. 18, no. 16, pp. 4415–4424, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. I. W. Y. Mak, N. Evaniew, S. Popovic, R. Tozer, and M. Ghert, “A translational study of the neoplastic cells of giant cell tumor of bone following neoadjuvant denosumab,” The Journal of Bone & Joint Surgery—American Volume, vol. 96, no. 15, article e127, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Hakozaki, T. Tajino, H. Yamada et al., “Radiological and pathological characteristics of giant cell tumor of bone treated with denosumab,” Diagnostic Pathology, vol. 9, no. 1, article 111, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. N. Santosh, J. L. Mayerson, and O. H. Iwenofu, “Pseudosarcomatous spindle cell proliferation with osteoid matrix mimicking osteosarcoma: a distinct histologic phenotype in giant cell tumor of bone following denosumab therapy,” Applied Immunohistochemistry & Molecular Morphology, 2015. View at Publisher · View at Google Scholar
  19. H. G. Bone, R. Chapurlat, M.-L. Brandi et al., “The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension,” Journal of Clinical Endocrinology and Metabolism, vol. 98, no. 11, pp. 4483–4492, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. K. Fizazi, M. Carducci, M. Smith et al., “Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study,” The Lancet, vol. 377, no. 9768, pp. 813–822, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. P. Peddi, M. A. Lopez-Olivo, G. F. Pratt, and M. E. Suarez-Almazor, “Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis,” Cancer Treatment Reviews, vol. 39, no. 1, pp. 97–104, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. M. R. Smith, F. Saad, R. Coleman et al., “Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial,” The Lancet, vol. 379, no. 9810, pp. 39–46, 2012. View at Publisher · View at Google Scholar · View at Scopus